305 related articles for article (PubMed ID: 32193838)
1. Immunomodulators in Lymphoma.
Anagnostou T; Ansell SM
Curr Treat Options Oncol; 2020 Mar; 21(4):28. PubMed ID: 32193838
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory Agents in Follicular Lymphoma.
Ysebaert L; Morschhauser F
Hematol Oncol Clin North Am; 2020 Aug; 34(4):715-726. PubMed ID: 32586576
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors: The linchpins of modern immunotherapy.
Wilky BA
Immunol Rev; 2019 Jul; 290(1):6-23. PubMed ID: 31355494
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions.
Hilmi M; Neuzillet C; Calderaro J; Lafdil F; Pawlotsky JM; Rousseau B
J Immunother Cancer; 2019 Nov; 7(1):333. PubMed ID: 31783782
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
Duan J; Wang Y; Jiao S
Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment.
Looi CK; Chung FF; Leong CO; Wong SF; Rosli R; Mai CW
J Exp Clin Cancer Res; 2019 Apr; 38(1):162. PubMed ID: 30987642
[TBL] [Abstract][Full Text] [Related]
7. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
Griggio V; Perutelli F; Salvetti C; Boccellato E; Boccadoro M; Vitale C; Coscia M
Front Immunol; 2020; 11():594556. PubMed ID: 33312177
[TBL] [Abstract][Full Text] [Related]
8. Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors.
Joshi M; Ansell SM
J Immunol Res; 2020; 2020():8820377. PubMed ID: 33294467
[TBL] [Abstract][Full Text] [Related]
9. Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma.
Lesokhin AM; Bal S; Badros AZ
Cancer Immunol Res; 2019 Aug; 7(8):1224-1229. PubMed ID: 31371317
[TBL] [Abstract][Full Text] [Related]
10. The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.
Vardhana S; Younes A
Haematologica; 2016 Jul; 101(7):794-802. PubMed ID: 27365459
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
12. Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade.
Wilkinson RW; Leishman AJ
Front Immunol; 2018; 9():1082. PubMed ID: 29910800
[TBL] [Abstract][Full Text] [Related]
13. Role of cell surface proteoglycans in cancer immunotherapy.
Espinoza-Sánchez NA; Götte M
Semin Cancer Biol; 2020 May; 62():48-67. PubMed ID: 31336150
[TBL] [Abstract][Full Text] [Related]
14. The potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers.
Liang J; Chen D; Chen L; She X; Zhang H; Xiao Y
Future Oncol; 2020 Jun; 16(17):1211-1223. PubMed ID: 32396026
[TBL] [Abstract][Full Text] [Related]
15. Immune biological rationales for the design of combined radio- and immunotherapies.
Hader M; Frey B; Fietkau R; Hecht M; Gaipl US
Cancer Immunol Immunother; 2020 Feb; 69(2):293-306. PubMed ID: 31953578
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
Xia Y; Medeiros LJ; Young KH
Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
[TBL] [Abstract][Full Text] [Related]
17. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.
Pauken KE; Dougan M; Rose NR; Lichtman AH; Sharpe AH
Trends Immunol; 2019 Jun; 40(6):511-523. PubMed ID: 31053497
[TBL] [Abstract][Full Text] [Related]
18. Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma.
Chin CK; Nastoupil LJ
Hematol Oncol Clin North Am; 2020 Aug; 34(4):743-756. PubMed ID: 32586578
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
Fares CM; Van Allen EM; Drake CG; Allison JP; Hu-Lieskovan S
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():147-164. PubMed ID: 31099674
[TBL] [Abstract][Full Text] [Related]
20. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.
Patel SA; Minn AJ
Immunity; 2018 Mar; 48(3):417-433. PubMed ID: 29562193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]